Related to OGT Awarded $3.6M for Next-Generation Sequencing

• Top 25 Biotech Companies
  Did your company make the list?
  
• Top 10 Pharma Firms
  Check out which companies made the list.
  
• Top 20 Pharma-Friendly Congress Members
  Who accepted the biggest pharmaceutical company contributions? Find out here.
  
• Top 15 CEO Salaries: Biotech Tool Providers
  Find out who's raking in the most in life science gadgetry.
  
• Candidates’ Science Answers Raise More Questions
  Presidental candidates’ responses to ScienceDebate.org query are inadequate and more discussion is essential.
  
• Virtual Companies’ Benefits, and Costs, All Too Real
  VCs are attracting Big Pharma’s attention, but data validation remains a problem.
  
• Top 20 Molecular Millionaires
  Which biopharma company leaders are raking in the most in shares?
  
• One Small Step, No Giant Leap for Privacy
  Privacy and Progress in Whole-Genome Sequencing report lacks implementation framework.
  
• Top 10 Best-Selling Drugs of the 21st Century
  Find out which drugs are in the most medicine cabinets.
  
• Slaying the Fungus Among Us
  Meningitis outbreak aggravates concerns about amphotericin B, as study begins shedding light on how the antifungal works.
  
• The Long and the Short of DNA Sequencing
  Third-generation sequencers improve on second-generation systems by offering longer reads.
  
• Drug Companies Exert Greater Influence on Development
  Government funding, once the norm, is declining and pharma firms are in the driver’s seat.
  
• Cliff Spells Danger for Biotechs
  If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment.
  
• Top 20 Venture Capital Firms
  Who invests the most funds in the most biotech companies?
  
• Crossing the Valley of Death
  BioMotiv says investments in drugs and technologies, not companies, will bring treatments to market faster.
  
• With GAIN, Less Pain
  Antibiotic drug developers welcome incentives, though cost, rules remain a challenge.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• Building a Self-Destructive Mosquito
  Genetically modified mosquitos could be a way to curb the spread of dengue fever in Florida.
  
• Not Quite 1918, but Flu Still Deadly
  Authorities and manufacturers look ahead to new vaccines and immunization efforts while scrambling to deal with spot shortages.
  
• SBIR Thinks Smaller
  New rules taking effect on January 28 aim to draw investor-owned smaller biopharmas to the federal grant program and STTR, its companion.